Related Experiment Videos
Botulinum toxin in fourth nerve palsies
L Garnham1, J M Lawson, D O'Neill
1Moorfields Eye Hospital, London, United Kingdom.
Australian and New Zealand Journal of Ophthalmology
|February 1, 1997
Summary
Botulinum toxin A (BTXA) is most effective for residual fourth nerve (IV N) palsy deviations, especially when injected into the inferior rectus muscle. It offers limited benefit as a primary treatment for chronic IV N palsy.
Area of Science:
- Ophthalmology
- Neurology
- Medical Therapeutics
Background:
- Fourth nerve (IV N) palsy management often involves surgery, which carries risks of unpredictable outcomes like over- or under-correction.
- Botulinum toxin A (BTXA) is not a routine treatment for IV N palsy.
Purpose of the Study:
- To evaluate the efficacy of Botulinum toxin A (BTXA) injections in managing fourth nerve (IV N) palsies.
- To compare BTXA efficacy as a primary therapy versus for residual deviations.
Main Methods:
- Retrospective review of 20 patients (aged 19-70) with unilateral/bilateral IV N palsies receiving BTXA injections.
- Injections targeted the inferior oblique or inferior rectus muscles.
- Follow-up averaged 19 months.
Main Results:
- BTXA as primary therapy showed limited success, particularly with inferior oblique injections.
- Five patients with inferior rectus BTXA were symptom-free; others proceeded to surgery or prisms.
- BTXA for residual deviations yielded long-term benefits in 90% of patients, especially with inferior rectus injections.
Conclusions:
- Botulinum toxin A (BTXA) is most beneficial for residual fourth nerve (IV N) palsy deviations, particularly when injected into the inferior rectus muscle.
- BTXA has limited value as a primary therapy for chronic IV N palsy.